Valneva: Phase 1 trial initiated in Zika virus

(CercleFinance.com) - Valneva announces the initiation of a Phase 1 trial, VLA1601-102, to evaluate the safety and immunogenicity of VLA1601, its second-generation inactivated and adjuvanted Zika virus (ZIKV) vaccine candidate.


There are no preventive vaccines or effective treatments against the Zika virus, which therefore remains a public health threat and has been included in the FDA's priority review voucher program for tropical diseases, it says.

The trial is expected to include around 150 participants aged 18 to 49 in the US. Participants will receive a low, medium or high dose of VLA1601. Initial data from the trial are expected in the first half of 2025.


Copyright (c) 2024 CercleFinance.com. All rights reserved.